This study is testing a combination of two drugs, Isatuximab and Lenalidomide, for people with multiple myeloma who have undergone an autologous stem cell transplant (ASCT). This treatment is for those who still have minimal residual disease (MRD-positive), meaning a very small amount of cancer cells remain after their transplant. Isatuximab is a monoclonal antibody, a type of drug that targets specific cells. The study aims to see how many participants achieve an MRD-negative complete response (no detectable cancer cells) after one year. You may be able to join if you are 18 or older and have multiple myeloma. The study plans to enroll 50 participants.

Study design

This is a Phase II study for 50 participants. It is a single-arm study, meaning all participants receive the same treatment.

What's involved

Participants will receive Isatuximab intravenously and Lenalidomide by mouth. Treatment will continue for up to 3 years, or until the disease worsens or side effects are too severe. You will have regular monitoring, including bone marrow examinations and MRD testing.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for disease response and bone marrow MRD status every 12 months for a total of 3 years, or until disease progression or unacceptable toxicity.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.